Skye Bioscience triples authorized shares to 300M following shareholder approval

Filed May 29, 2026 · Period ending May 26, 2026 · ~1 min read

Key Changes

• high

  Authorized common stock increased from 100 million to 300 million shares via charter amendment filed May 28, 2026. This allows the company to issue up to 200 million additional shares for future capital raises, acquisitions, or compensation without immediate dilution.

  Item 5.03 verify on EDGAR →
• medium

  Shareholders approved the authorized share increase at the May 26 annual meeting with 88% support (20.6M for, 2.9M against). The Board had unanimously recommended approval in the April proxy statement.

  Item 5.07 verify on EDGAR →
• medium

  Currently outstanding shares remain unchanged at approximately 35.1 million. The amendment only expands the pool of shares available for future issuance, not shares currently in circulation.

  Item 5.03 verify on EDGAR →